Carboplatin (CBDCA), iproplatin (CHIP), and high dose cisplatin in hypertonic saline evaluated for tubular nephrotoxicity
dc.contributor.author | Wright, Reba K. | en_US |
dc.contributor.author | Kamen, Barton A. | en_US |
dc.contributor.author | Goren, Marshall P. | en_US |
dc.contributor.author | Dodge, Richard K. | en_US |
dc.contributor.author | Pratt, Charles B. | en_US |
dc.contributor.author | Forastiere, Arlene A. | en_US |
dc.contributor.author | Horowitz, Marc E. | en_US |
dc.date.accessioned | 2006-09-11T18:22:20Z | |
dc.date.available | 2006-09-11T18:22:20Z | |
dc.date.issued | 1987-02 | en_US |
dc.identifier.citation | Goren, Marshall P.; Forastiere, Arlene A.; Wright, Reba K.; Horowitz, Marc E.; Dodge, Richard K.; Kamen, Barton A.; Pratt, Charles B.; (1987). "Carboplatin (CBDCA), iproplatin (CHIP), and high dose cisplatin in hypertonic saline evaluated for tubular nephrotoxicity." Cancer Chemotherapy and Pharmacology 19(1): 57-60. <http://hdl.handle.net/2027.42/46915> | en_US |
dc.identifier.issn | 1432-0843 | en_US |
dc.identifier.issn | 0344-5704 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/46915 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=2880677&dopt=citation | en_US |
dc.description.abstract | We compared the acute tubular nephrotoxicity of three platinum compounds in children and adults with solid tumors by monitoring the urinary excretion of alanine aminopeptidase, N -acetyl-β-D-glucosaminidase, and total protein. Cisplatin (100 mg/m 2 ) was administered with mannitol, or at a twofold larger total dosage (50 mg/m 2 per day for 4 days) in a 3% saline infusion. Carboplatin (300 mg/m 2 ) was administered in combination with 5-fluorouracil, and iproplatin was administered in dosages ranging from 216 to 388 mg/m 2 . Enzymuria and proteinuria induced by cisplatin at a total dosage of 200 mg/m 2 on a divided schedule did not significantly differ from that observed for the single 100 mg/m 2 dose. Enzymuria and proteinuria induced by carboplatin and iproplatin were significantly less than that for cisplatin; however, one patient developed chronic tubular damage after three courses of carboplatin, and the acute tubular toxicity of iproplatin in one of 15 patients was exceptional. Our findings support the value of administering cisplatin in hypertonic saline on a divided schedule as a strategy to reduce acute tubular damage. Although carboplatin and iproplatin are less nephrotoxic than cisplatin, occasionally patients experience subclinical acute or chronic tubular damage that may lead to overt nephrotoxicity with continued therapy. | en_US |
dc.format.extent | 456218 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Springer-Verlag | en_US |
dc.subject.other | Cancer Research | en_US |
dc.subject.other | Pharmacology/Toxicology | en_US |
dc.subject.other | Oncology | en_US |
dc.subject.other | Biomedicine | en_US |
dc.title | Carboplatin (CBDCA), iproplatin (CHIP), and high dose cisplatin in hypertonic saline evaluated for tubular nephrotoxicity | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Radiology | en_US |
dc.subject.hlbsecondlevel | Chemistry | en_US |
dc.subject.hlbsecondlevel | Chemical Engineering | en_US |
dc.subject.hlbsecondlevel | Biological Chemistry | en_US |
dc.subject.hlbtoplevel | Engineering | en_US |
dc.subject.hlbtoplevel | Science | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | The Department of Internal Medicine, Division of Hematology-Oncology, University of Michigan Medical Center, Ann Arbor, Michigan, USA | en_US |
dc.contributor.affiliationother | The Department of Pediatrics and Pharmacology, University of Texas Health Sciences Center, Dallas, Texas, USA | en_US |
dc.contributor.affiliationother | The Department of Pathology and Laboratory Medicine, St. Jude Children's Research Hospital, Memphis, Tennessee, USA; Clinical Chemistry, St. Jude Children's Research Hospital, 332 North Lauderdale, P. O. Box 318, 38101, Memphis, TN, USA | en_US |
dc.contributor.affiliationother | The Department of Pathology and Laboratory Medicine, St. Jude Children's Research Hospital, Memphis, Tennessee, USA | en_US |
dc.contributor.affiliationother | Department of Hematology-Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA; Department of Pediatrics, University Tennessee Center Health Sciences, Memphis, Tennessee, USA | en_US |
dc.contributor.affiliationother | Division of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA | en_US |
dc.contributor.affiliationother | Department of Hematology-Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA; Department of Pediatrics, University Tennessee Center Health Sciences, Memphis, Tennessee, USA | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 2880677 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/46915/1/280_2004_Article_BF00296257.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1007/BF00296257 | en_US |
dc.identifier.source | Cancer Chemotherapy and Pharmacology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.